Logo image of DNA

GINKGO BIOWORKS HOLDINGS INC (DNA) Stock Price, Quote, News and Overview

NYSE:DNA - New York Stock Exchange, Inc. - US37611X2099 - Common Stock - Currency: USD

13.32  -0.64 (-4.58%)

DNA Quote, Performance and Key Statistics

GINKGO BIOWORKS HOLDINGS INC

NYSE:DNA (8/7/2025, 3:54:09 PM)

13.32

-0.64 (-4.58%)

Sector
GICS SectorMaterials
GICS IndustryChemicals
GICS IndustryGroupMaterials
GICS SubIndustrySpecialty Chemicals
Statistics
52 Week High16.85
52 Week Low5
Market Cap739.66M
Shares55.53M
Float42.55M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO04-19 2021-04-19


DNA short term performance overview.The bars show the price performance of DNA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

DNA long term performance overview.The bars show the price performance of DNA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40 -60 -80

The current stock price of DNA is 13.32 USD. In the past month the price increased by 26.11%. In the past year, price increased by 29.16%.

GINKGO BIOWORKS HOLDINGS INC / DNA Daily stock chart

DNA Competitors/Peers

The largest stocks on the US markets in the "Specialty Chemicals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
SHW SHERWIN-WILLIAMS CO/THE 31.56 87.27B
ECL ECOLAB INC 38.31 76.36B
DD DUPONT DE NEMOURS INC 15.87 29.62B
PPG PPG INDUSTRIES INC 13.81 24.08B
IFF INTL FLAVORS & FRAGRANCES 14.74 16.44B
RPM RPM INTERNATIONAL INC 22.4 15.24B
SQM QUIMICA Y MINERA CHIL-SP ADR 18.23 10.99B
ALB ALBEMARLE CORP N/A 8.24B
EMN EASTMAN CHEMICAL CO 8 7.06B
NEU NEWMARKET CORP 14.28 6.80B
AXTA AXALTA COATING SYSTEMS LTD 11.74 6.21B
ESI ELEMENT SOLUTIONS INC 16.29 5.73B

About DNA

Company Profile

DNA logo image Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 834 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.

Company Info

GINKGO BIOWORKS HOLDINGS INC

27 Drydock Avenue, 8th Floor

Boston MASSACHUSETTS US

CEO: Harry E. Sloan

Employees: 1218

DNA Company Website

DNA Investor Relations

Phone: 18774425362

GINKGO BIOWORKS HOLDINGS INC / DNA FAQ

What is the stock price of GINKGO BIOWORKS HOLDINGS INC today?

The current stock price of DNA is 13.32 USD. The price decreased by -4.58% in the last trading session.


What is the ticker symbol for GINKGO BIOWORKS HOLDINGS INC stock?

The exchange symbol of GINKGO BIOWORKS HOLDINGS INC is DNA and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is DNA stock listed?

DNA stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for GINKGO BIOWORKS HOLDINGS INC stock?

11 analysts have analysed DNA and the average price target is 8.84 USD. This implies a price decrease of -33.63% is expected in the next year compared to the current price of 13.32. Check the GINKGO BIOWORKS HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GINKGO BIOWORKS HOLDINGS INC worth?

GINKGO BIOWORKS HOLDINGS INC (DNA) has a market capitalization of 739.66M USD. This makes DNA a Small Cap stock.


How many employees does GINKGO BIOWORKS HOLDINGS INC have?

GINKGO BIOWORKS HOLDINGS INC (DNA) currently has 1218 employees.


What are the support and resistance levels for GINKGO BIOWORKS HOLDINGS INC (DNA) stock?

GINKGO BIOWORKS HOLDINGS INC (DNA) has a support level at 12.83 and a resistance level at 14.73. Check the full technical report for a detailed analysis of DNA support and resistance levels.


Is GINKGO BIOWORKS HOLDINGS INC (DNA) expected to grow?

The Revenue of GINKGO BIOWORKS HOLDINGS INC (DNA) is expected to decline by -21.75% in the next year. Check the estimates tab for more information on the DNA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GINKGO BIOWORKS HOLDINGS INC (DNA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GINKGO BIOWORKS HOLDINGS INC (DNA) stock pay dividends?

DNA does not pay a dividend.


What is the Price/Earnings (PE) ratio of GINKGO BIOWORKS HOLDINGS INC (DNA)?

GINKGO BIOWORKS HOLDINGS INC (DNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.42).


What is the Short Interest ratio of GINKGO BIOWORKS HOLDINGS INC (DNA) stock?

The outstanding short interest for GINKGO BIOWORKS HOLDINGS INC (DNA) is 24.3% of its float. Check the ownership tab for more information on the DNA short interest.


DNA Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to DNA. When comparing the yearly performance of all stocks, DNA is one of the better performing stocks in the market, outperforming 92.85% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

DNA Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to DNA. No worries on liquidiy or solvency for DNA as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DNA Financial Highlights

Over the last trailing twelve months DNA reported a non-GAAP Earnings per Share(EPS) of -7.42. The EPS increased by 57.84% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -36.5%
ROE -72.92%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%47.5%
Sales Q2Q%27.34%
EPS 1Y (TTM)57.84%
Revenue 1Y (TTM)13.76%

DNA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 42% to DNA. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 30.78% and a revenue growth -21.75% for DNA


Ownership
Inst Owners69.9%
Ins Owners6.63%
Short Float %24.3%
Short Ratio7.06
Analysts
Analysts41.82
Price Target8.84 (-33.63%)
EPS Next Y30.78%
Revenue Next Year-21.75%